Thomas James Doyle Sells 7,142 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 7,142 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $60,421.32. Following the sale, the senior vice president directly owned 145,167 shares in the company, valued at approximately $1,228,112.82. This trade represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Thomas James Doyle also recently made the following trade(s):

• On Friday, November 14th, Thomas James Doyle sold 4,539 shares of Kura Oncology stock. The shares were sold at an average price of $11.18, for a total transaction of $50,746.02.

Kura Oncology Trading Down 5.1%

Shares of Kura Oncology stock opened at $8.04 on Thursday. The firm has a 50-day simple moving average of $10.26 and a two-hundred day simple moving average of $9.05. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The company has a market cap of $699.64 million, a P/E ratio of -3.24 and a beta of 0.25.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The business had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. As a group, equities analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently modified their holdings of KURA. Rhumbline Advisers lifted its position in shares of Kura Oncology by 0.9% during the third quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock worth $1,061,000 after purchasing an additional 1,039 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Kura Oncology by 9.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 20,993 shares of the company’s stock worth $217,000 after buying an additional 1,825 shares in the last quarter. Flower City Capital lifted its holdings in Kura Oncology by 20.0% during the 4th quarter. Flower City Capital now owns 12,000 shares of the company’s stock worth $125,000 after buying an additional 2,000 shares in the last quarter. Profund Advisors LLC boosted its position in Kura Oncology by 11.1% in the 3rd quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock valued at $220,000 after buying an additional 2,478 shares during the period. Finally, Arizona State Retirement System grew its stake in shares of Kura Oncology by 15.8% in the third quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock worth $181,000 after acquiring an additional 2,802 shares in the last quarter.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Neutral Sentiment: Recent analyst activity is mixed — several firms (JMP, Leerink, HC Wainwright) maintain positive ratings and high price targets while others (Zacks, Weiss) issued negative views. The consensus remains a “Moderate Buy” but with divergent opinions that can sustain volatility for the stock. Analyst Coverage Summary
• Neutral Sentiment: Institutions hold large positions and some have increased stakes (Vanguard, EcoR1, Jacobs Levy, Geode, Qube Research). Significant institutional ownership can cushion price moves, though it also means bigger blocks could trade. Institutional Holdings Detail
• Negative Sentiment: Multiple insider sales reported on Jan. 27–28: SVP Teresa Brophy Bair sold 11,208 shares; Mollie Leoni sold 8,180; Thomas J. Doyle (SVP) sold 7,142; Brian T. Powl sold 6,414; COO Kathleen Ford sold 1,813; and Francis Burrows sold 1,311 — all at about $8.46 per share. The cluster of executive sales (reductions of ~1–4.7% of post-trade holdings for each insider) is weighing on sentiment because coordinated or same‑day sales by multiple insiders often trigger investor concern about near-term outlook or liquidity needs. Insider Trades Report

Analyst Upgrades and Downgrades

Several analysts recently issued reports on KURA shares. JMP Securities reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. UBS Group increased their price target on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 14th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Tuesday, January 13th. Barclays restated an “overweight” rating and issued a $28.00 target price (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Finally, Wedbush reiterated an “outperform” rating and set a $38.00 price target (up previously from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.